Beyond PEG: Emerging Polymer Lipid Alternatives for Lipid Nanoparticle (LNP) Formulations
Advanced Science · 2026-09 · 13 (50)
DOI: 10.1002/advs.77145 ↗At a glance
Übersichtsarbeit in Advanced Science, published online on 2026-08-12. Written by Zihnil A I Mazrad and 4 co-authors. Institution: Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. Major MEDLINE topics: Polyethylene Glycols, Nanoparticles, Lipids, Polymers. Cited 7 times so far (Crossref); 100 references. The full text is freely available (open access, CC BY 4.0). Funded by: Australian Research Council, Australian Government MRFF, National Health and Medical Research Council.
Abstract (original language)
Lipid nanoparticles (LNPs) have rapidly emerged as the leading delivery platform for nucleic acid therapeutics due to their high encapsulation efficiency, scalable manufacturing, and clinical success in siRNA and mRNA medicines. Poly(ethylene glycol)‐lipids ((PEG)–lipids) have been central to this progress by providing steric stabilization, size control, and tunable biodistribution. However, PEGylation also introduces important limitations, including complement activation, pre‐existing and treatment‐induced anti‐PEG antibodies, and accelerated blood clearance, which increasingly constrain repeated and long‐term dosing strategies. This review focuses on recent advances in PEG‐alternative LNP designs, including non‐PEG polymers, zwitterionic and biomimetic lipids, polypeptides, and structurally modified PEG analogues. We compare how polymer chemistry, anchor geometry, and grafting architecture influence LNP formation, physicochemical properties, biodistribution, cellular uptake, and immunological outcomes. Moreover, we discuss key challenges that remain in translating PEG‐free and PEG‐modified LNPs toward clinical application and propose future directions to better understand in vivo behavior and enable rational design of next‐generation stealth LNPs. Overall, PEG lipid alternatives should not be viewed as simple PEG mimics, but as distinct surface‐engineering materials that create new nano‐bio interfaces and reshape LNP behavior in biological systems.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
- Materials Science and Engineering, Monash University, Clayton, Victoria, Australia.
- Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Heidelberg, Victoria, Australia.
- Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
- Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia.
ORCID profiles: Yi Ju, Stephen J Kent, Kristian Kempe
Funding
- Australian Research Council
- Australian Government MRFF
- National Health and Medical Research Council
Cite
APA
Mazrad, Z. A. I., Ju, Y., Kent, S. J., Pouton, C. W., & Kempe, K. (2026). Beyond PEG: Emerging Polymer Lipid Alternatives for Lipid Nanoparticle (LNP) Formulations. Advanced Science, 13(50). https://doi.org/10.1002/advs.77145
Vancouver
Mazrad ZAI, Ju Y, Kent SJ, Pouton CW, Kempe K. Beyond PEG: Emerging Polymer Lipid Alternatives for Lipid Nanoparticle (LNP) Formulations. Advanced Science. 2026;13(50). doi:10.1002/advs.77145
BibTeX
@article{Mazrad2026,
author = {Mazrad, Zihnil A I and Ju, Yi and Kent, Stephen J and Pouton, Colin W and Kempe, Kristian},
title = {Beyond PEG: Emerging Polymer Lipid Alternatives for Lipid Nanoparticle (LNP) Formulations},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {50},
doi = {10.1002/advs.77145}
}
EUVIMED